1. Home
  2. CLDX

CLDX

Celldex Therapeutics Inc.

Logo Celldex Therapeutics Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-24-2024 2:30pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Founded: N/A Country:
N/A
Employees: N/A City: HAMPTON
Market Cap: 2.6B IPO Year: 2008
Target Price: $66.00 AVG Volume (30 days): 948.4K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.92 EPS Growth: N/A
52 Week Low/High: $22.11 - $53.18 Next Earning Date: 01-01-0001
Revenue: $6,883,000 Revenue Growth: 192.02%
Revenue Growth (this year): -53.32% Revenue Growth (next year): -12.45%

Share on Social Networks: